LUNG Share Price Performance
US$1.61
-4.32 (-72.85%)
82.6% undervalued intrinsic discount
US$9.25
Fair Value
Price US$1.61
AnalystConsensusTarget US$9.25
Fair ValueUS$9.25
Share PriceUS$1.61
82.6% undervalued intrinsic discount
LUNG Community Narratives
AN
Fair Value US$9.25 82.6% undervalued intrinsic discount
LungTrax And Global Expansion Will Broaden Market Access
0users have liked this narrative
1users have commented on this narrative
0users have followed this narrative
LUNG Community Fair Values
- AN
Consensus Narrative from 6 AnalystsLungTrax And Global Expansion Will Broaden Market Access
Key Takeaways Expansion into new markets and innovative tools like LungTrax could grow patient volume, boosting revenue and operational efficiency. Global growth in Europe, China, and potential in Japan supports geographical diversification and long-term revenue opportunities.US$9.25FV82.6% undervalued intrinsic discount21.82%Revenue growth p.a.0users have liked this narrative1users have commented on this narrative0users have followed this narrativeUpdated narrative
Recent LUNG News & Updates
No updates
Pulmonx Corporation Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -1.40
- Gross Margin
- 73.07%
- Net Profit Margin
- -62.88%
- Debt/Equity Ratio
- 53.7%
Pulmonx Corporation Competitors
About LUNG
- Founded
- 1995
- Employees
- 291
- CEO
- WebsiteView website
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
U.S. Market Performance
- 7 Days: -1.2%
- 3 Months: 12.3%
- 1 Year: 21.3%
- Year to Date: 7.0%
In the last week, the market has fallen 1.2%, dragged down most by the Consumer Discretionary. In contrast to the last week, the market is actually up 21% over the past year. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading